ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism (COBRRA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03266783
Recruitment Status : Recruiting
First Posted : August 30, 2017
Last Update Posted : July 10, 2018
Sponsor:
Collaborator:
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Ottawa Hospital Research Institute

Brief Summary:
Apixaban and rivaroxaban have been compared to standard therapy for treatment of acute symptomatic venous thromboembolism (VTE) in randomized controlled trials (RCTs), and are both approved by Health Canada. No safety or efficacy data is available from direct head-to-head comparison of these two anticoagulants. Lawsuits in the United States over bleeding events, patient perceptions, and concerns with medication adherence are additional factors highlighting the importance of a comparison trial. This multi-center, pragmatic, prospective, randomized, open-label, blinded end-point (PROBE) trial aims to compare the safety of apixaban and rivaroxaban for the treatment of VTE.

Condition or disease Intervention/treatment Phase
Venous Thromboembolism Drug: Apixaban Drug: Rivaroxaban Phase 4

Detailed Description:

VTE is the third leading cause of mortality by cardiovascular disease. Standard treatment for acute VTE uses a combination of parenteral Low-Molecular-Weight Heparin (LMWH) and oral vitamin K antagonists (VKA) for 3 months, and carries significant bleeding risk. The major and/or clinically-relevant non-major bleeding (CRNMB) event rate is reported between 8.1-9.7% during initial treatment. This treatment is burdensome owing to subcutaneous injections, drug interactions, and laboratory monitoring. Direct oral anticoagulants (DOACs) are simpler to use and do not require laboratory monitoring.

Rivaroxaban and apixaban are two DOACs targeting Factor Xa. Each DOAC was separately proven effective and safe when compared to standard treatment. Comparison of the bleeding rates between studies would favour use of apixaban over rivaroxaban; however, trial limitations and lack of direct comparison between these two agents makes it impossible to draw firm conclusions. This represents a dilemma in clinical practice because the absence of convincing differences in safety has led to genuine uncertainty about which DOAC has the best risk-to-benefit ratio.

To address these limitations, a head-to-head randomized controlled trial (RCT) is needed to determine the safety (i.e. bleeding risk) of twice daily apixaban over once daily rivaroxaban during the first 3 months of acute VTE treatment. Eligibility criteria will be less stringent than the COBRRA pilot study and reflect real-world patients. Cost-effective analysis of apixaban twice daily compared to rivaroxaban once daily will also be performed.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2760 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Actual Study Start Date : December 13, 2017
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : May 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding

Arm Intervention/treatment
Active Comparator: Apixaban group
10 mg PO BID for 1 week, then 5 mg PO BID for 3 months of treatment
Drug: Apixaban
Refer to Apixaban group
Other Name: Eliquis

Active Comparator: Rivaroxaban group
15 mg PO BID for 3 weeks, then 20 mg PO OD for 3 months of treatment
Drug: Rivaroxaban
Refer to Rivaroxaban group
Other Name: Xarelto




Primary Outcome Measures :
  1. The rate of adjudicated clinically relevant bleeding (CRB) events [ Time Frame: For the duration of the study: 3 months ]
    CRB events are defined as the composite of major bleeding (MB) events and clinically relevant non-major bleeding (CRNMB) events.


Secondary Outcome Measures :
  1. Adjudicated Major Bleeding events [ Time Frame: For the duration of the study: 3 months ]
  2. Adjudicated Clinically Relevant Non-Major Bleeding events [ Time Frame: For the duration of the study: 3 months ]
  3. Adjudicated recurrent VTE events [ Time Frame: For the duration of the study: 3 months ]
  4. Adjudicated VTE-related deaths [ Time Frame: For the duration of the study: 3 months ]
  5. All-cause mortality [ Time Frame: For the duration of the study: 3 months ]
  6. Medication adherence [ Time Frame: For the duration of the study: 3 months ]
  7. Quality-adjusted life years (QALYs) gained [ Time Frame: For the duration of the study: 3 months ]
  8. Incremental cost-effectiveness ratio [ Time Frame: For the duration of the study: 3 months ]
  9. Impact of verbal consent on patient participation in comparison with participants from sites using written informed consent [ Time Frame: For the duration of the study: 3 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed newly diagnosed symptomatic acute VTE (proximal power extremity DVT or segmental or greater PE)
  • Age ≥ 18 years old
  • Informed consent obtained

Exclusion Criteria:

  • Have received > 72 hours of therapeutic anticoagulation
  • Creatinine clearance < 30 ml/min calculated with the Cockcroft-Gault formula
  • Any contraindication for anticoagulation with apixaban or rivaroxaban as determined by the treating physician such as, but not limited to:

    • active bleeding,
    • active malignancy, defined as a) diagnosed with cancer within the past 6 months; or b) recurrent, regionally advanced or metastatic disease; or c) currently receiving treatment or have received any treatment for cancer during the 6 months prior to randomization; or d) a hematologic malignancy not in complete remission,
    • weight > 120 kg,
    • liver disease (Child-Pugh Class B or C),
    • use of contraindicated medications
    • another indication for long-term anticoagulation (e.g. atrial fibrillation)
    • pregnant (note below) or breastfeeding (Note: as reported by the patient or a pregnancy test will be ordered at the discretion of the treating physician for women of childbearing potential as per standard of care)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03266783


Contacts
Contact: Lana Castellucci, MD, FRCPC 613-737-8899 ext 73682 lcastellucci@toh.on.ca
Contact: Yan Yu He, MSc 613-737-8899 ext 72103 yahe@ohri.ca

Locations
Canada, Alberta
University of Calgary Not yet recruiting
Calgary, Alberta, Canada
Contact: Deepa Suryanarayan, MD         
Alberta Health Sciences Recruiting
Edmonton, Alberta, Canada
Contact: Cynthia Wu, MD         
Canada, British Columbia
St. Paul's Hospital Not yet recruiting
Vancouver, British Columbia, Canada
Contact: Tony Wan, MD         
Canada, Nova Scotia
QEII Health Science Centre Recruiting
Halifax, Nova Scotia, Canada, B3H 2Y9
Contact: Sudeep Shivakumar, MD         
Canada, Ontario
Cornwall Hospital Not yet recruiting
Cornwall, Ontario, Canada
Contact: Nancy McDonald, RN         
Hamilton General Hospital Recruiting
Hamilton, Ontario, Canada
Contact: Kerstin de Wit, MD         
Juravinski Hospital Recruiting
Hamilton, Ontario, Canada
Contact: Kerstin de Wit, MD         
St. Joseph's Healthcare Hamilton Recruiting
Hamilton, Ontario, Canada
Contact: James Douketis, MD         
London Health Sciences Center Not yet recruiting
London, Ontario, Canada, N6A 5W9
Contact: Michael Kovacs, MD         
The Ottawa Hospital - General Campus Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Lana Castellucci, MD, FRCPC    613-737-8899 ext 73682    lcastellucci@toh.on.ca   
Contact: Yan Yu He, MSc    613-737-8899 ext 72103    yahe@ohri.ca   
Principal Investigator: Lana Castellucci, MD, FRCPC         
Sub-Investigator: Marc Carrier, MD, FRCPC         
Canada, Quebec
St. Mary's Hospital Not yet recruiting
Montreal, Quebec, Canada
Contact: Susan Solymoss, MD         
Jewish General Hospital Not yet recruiting
Montréal, Quebec, Canada, H3T 1E2
Contact: Susan Kahn, MD, FRCPC         
McGill University Health Center Not yet recruiting
Montréal, Quebec, Canada, H4A 3J1
Contact: Susan Solymoss, MD         
, CHU de Québec- Enfant-Jésus Not yet recruiting
Quebec city, Quebec, Canada
Contact: Benoit Cote, MD         
Sponsors and Collaborators
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR)
Investigators
Principal Investigator: Lana Castellucci, MD, FRCPC Ottawa Hospital Research Institute

Responsible Party: Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier: NCT03266783     History of Changes
Other Study ID Numbers: COBRRA
First Posted: August 30, 2017    Key Record Dates
Last Update Posted: July 10, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Embolism and Thrombosis
Thromboembolism
Venous Thromboembolism
Vascular Diseases
Cardiovascular Diseases
Rivaroxaban
Apixaban
Factor Xa Inhibitors
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants